Brokers Offer Predictions for TSE:PRN FY2024 Earnings

Profound Medical Corp. (TSE:PRN) – Research analysts at Leede Financial issued their FY2024 EPS estimates for shares of Profound Medical in a research note issued to investors on Monday, November 4th. Leede Financial analyst D. Loe anticipates that the company will earn ($1.27) per share for the year. The consensus estimate for Profound Medical’s current full-year earnings is ($1.90) per share. Leede Financial also issued estimates for Profound Medical’s FY2025 earnings at ($0.28) EPS and FY2026 earnings at $0.14 EPS.

Profound Medical (TSE:PRN) last announced its quarterly earnings results on Thursday, August 8th. The company reported C($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of C($0.38). The business had revenue of C$3.06 million during the quarter, compared to analyst estimates of C$3.42 million.

Profound Medical Trading Down 3.7 %

Shares of TSE PRN opened at C$10.94 on Wednesday. The company has a debt-to-equity ratio of 16.95, a quick ratio of 14.98 and a current ratio of 8.61. Profound Medical has a 52-week low of C$9.55 and a 52-week high of C$16.00. The firm has a 50 day moving average price of C$10.81 and a two-hundred day moving average price of C$11.51. The stock has a market cap of C$267.81 million, a P/E ratio of -6.59 and a beta of 0.81.

Insider Buying and Selling at Profound Medical

In other Profound Medical news, Senior Officer Rashed Osman Dewan purchased 9,765 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was purchased at an average cost of C$12.85 per share, for a total transaction of C$125,480.25. Corporate insiders own 8.62% of the company’s stock.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.